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http://www.biomedcentral.com/1471-2407/14/147RESEARCH ARTICLE Open AccessInvasive neuroendocrine carcinoma of the breast:
a population-based study from the surveillance,
epidemiology and end results (SEER) database
Jun Wang1,3, Bing Wei2,3, Constance T Albarracin3, Jianhua Hu4, Susan C Abraham3 and Yun Wu3*Abstract
Background: Neuroendocrine carcinoma (NEC) of the breast is a rare type of carcinoma that has not been well
studied or characterized. Of the limited number of studies reported in the literature, most are case reports. A few
small retrospective series studies have been reported.
Methods: We reviewed data on 142 cases of mammary NEC recorded in the surveillance, epidemiology, and end
results (SEER) database during 2003–2009 and evaluated disease incidence and patient age, sex, and race/ethnicity;
clinicopathologic characteristics; and survival in comparison to invasive mammary carcinoma, not otherwise
specified. We also performed univariate and multivariate analyses to identify prognostic factors in this disease.
Results: Review of the 142 SEER cases revealed that NEC is an aggressive variant of invasive mammary carcinoma.
It generally occurred in older women (>60 years); present with larger tumor size (>20 mm), higher histologic grade,
and higher clinical stage; and result in shorter overall survival and disease-specific survival than invasive mammary
carcinoma, not otherwise specified (IMC-NOS). Overall survival and disease-specific survival were shorter in NEC at
each stage than in IMC-NOS of the same stage. Furthermore, when all NEC and IMC-NOS cases were pooled
together, neuroendocrine differentiation itself was an adverse prognostic factor independent of other known
prognostic factors, including age, tumor size, nodal status, histologic grade, estrogen/progesterone receptor status,
and therapy.
Conclusions: NEC is a rare but aggressive type of mammary carcinoma. Novel therapeutic approaches should be
explored for this uniquely clinical entity.
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Neuroendocrine carcinoma (NEC) of the breast is a very
rare malignant tumor. Only a limited number of studies
on NEC have been reported in the literature, most of
them anecdotal case reports. Very few are series studies
[1-11]. Much of the current limited knowledge of this
disease is based on these small retrospective series and
thus is subject to selection/referral bias. Therefore, very
little is known about the disease incidence, age and sex
predilection, race/ethnicity distribution, clinicopathologic
characteristics, and survival.* Correspondence: yunwu@mdanderson.org
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reproduction in any medium, provided the orTo gain more insight into mammary NEC, we took
advantage of a large database of cancer cases collected
during the last two decades from surveillance, Epidemi-
ology, and end results (SEER) registries. Using SEER
data, we evaluated the incidence and clinical course of
mammary NEC in comparison to its more common coun-
terpart, invasive mammary carcinoma, not otherwise spe-
cified (IMC-NOS).Methods
Data acquisition and patient selection
We utilized SEER data released in April 2012 [12]. The
SEER database includes data from 9 population-based
registries (1990–1999) and 18 population-based registries
(2000–2009) which cover approximately 26% of U.S. cancertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Baseline demographic and clinicopathologic features of the mammary NEC cohort and the invasive mammary
carcinoma control cohort from the SEER database (2003–2009)
Characteristics NEC Invasive mammary carcinoma P
Age, years, mean ± SD 63.6 ± 14.9 61.3 ± 14.2 0.029
Tumor size (mm), mean ± SD 31.9 ± 31.1 22.5 ± 24.1 <0.0001
No. of patients % No. of patients %
Sex 0.06a
Male 3 2.1 2,909 0.8
Female 139 97.9 378,735 99.2
Race NS
White 121 85.2 312,513 81.9
Black 13 9.2 38,975 10.2
Other 8 5.6 30,156 7.9
AJCC TNM stage <0.0001*
I 32 22.5 173,349 45.4
II 52 36.6 125,129 32.8
III 16 11.3 42,020 11.0
IV 34 23.9 18,844 4.9
Unknown 8 5.6 22,302 5.8
Regional lymph node 0.05*
Negative 52 36.6 214,745 56.3
Positive 40 28.2 109,741 28.8
Unknown 50 35.2 57,158 14.9
Grade <0.0001*
I 17 12.0 75,043 19.7
II 30 21.1 147,540 38.7
III 60 42.3 126,919 33.3
Unknown 35 24.7 32,142 8.3
ER status 0.003**
Negative 37 26.1 74,093 19.4
Borderline 0 0 812 0.2
Positive 77 54.2 274,474 71.9
Unknown 28 19.7 32,265 8.5
PR status <0.0001**
Negative 59 41.6 114,069 29.9
Borderline 0 0 2,626 0.7
Positive 53 37.3 228,877 60.0
Unknown 30 21.1 36,214 9.5
Surgery <.0001*
No 33 23.2 28,888 7.6
Yes 109 76.8 352,865 92.4
Radiation 0.038
No 91 64.1 211,458 55.4
Yes 51 35.9 170,186 44.6
NEC, neuroendocrine carcinoma; TNM, tumor-lymph nodes-metastasis; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor; NS, not significant.
aFisher exact test.
*Cases with other or unknown status were excluded from statistical analysis.
**Cases with borderline or unknown status were excluded from statistical analysis.
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Table 2 Overall survival in NEC cohort and invasive
mammary carcinoma cohort according to clinical stage
(2003–2009)






NEC 135 26 (12–48) 53.6 (42.2-63.7)
IMC 374,598 34 (16–56) 79.8 (79.6-79.9)
Stage I 0.002
NEC 32 33 (17–51) 74.4 (43.4-90.0)
IMC 170,778 36 (18–58) 89.6 (89.2-89.6)
Stage II <0.0001
NEC 49 30 (19–52) 73.9 (56.3-85.3)
IMC 123,430 36 (17–58) 82.4 (82.1-82.7)
Stage III 0.014
NEC 16 19 (13–41) 58.2 (21.0-82.8)
IMC 41,422 29 (14–48) 72.4 (71.8-73.1)
Stage IV NS
NEC 32 12 (4–25) 20.7 (5.70-42.1)
IMC 17,830 15 (5–30) 27.9 (26.9-29.0)
Data from the Surveillance, Epidemiology and End Results Program, 2003 to
2009. NEC, neuroendocrine carcinoma; IMC, invasive mammary carcinoma; IQR,
interquartile range; OS, overall survival; n, number of cases; HR, hazard ratio;
CI, confidence interval; NS, not significant.
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topography information on the basis of the third edition of
the International Classifications of Diseases for Oncology
(ICD-O-3). We included all cases of invasive carcinoma
(behavior code/3) of the breast (C500-509) and the study
cohort of mammary NEC (8013/3 and 8246/3). No mam-
mary NEC cases were identified in the SEER database be-
fore 1998. Of note, mammary NEC was strictly defined for
the first time in 2003 by the World Health Organization
(WHO) as >50% of the tumor cells expressing neuroendo-
crine markers [13]. We, therefore, focused our study on
cases diagnosed from 2003 to 2009. Patients with stage I-IV
invasive mammary carcinoma diagnosed between 2003 and
2009 were identified from the SEER database (n = 381,644)
to compare with the NEC cohort (n = 142). We also
performed survival analyses on 72 cases of mammary
NEC and 382,453 control cases of IMC, NOS identified
from the SEER database based on the same ICD codes
between 1998 and 2002.
Data analysis
Descriptive statistics were calculated for demographic and
clinicopathologic factors, and differences in these between
the NEC and IMC-NOS cohorts were evaluated using the
chi-square or Fisher exact test, as appropriate. Age and
tumor size were analyzed as continuous variables, and
statistical differences in the mean values were assessed
using the Student t-test. Rates of disease-specific survival
(DSS) and overall survival (OS) were used as primary
endpoints. Survival was measured from the date of diagno-
sis to the date of death, the date last known to be alive, or
November 30, 2009. To determine the effects of differ-
ent variables on OS and DSS, we performed a univari-
ate survival analysis using the Kaplan-Meier method,
and the significance was assessed using the log-rank
test. A multivariate analysis was performed using the
Cox proportional hazards model. The estimated risks
for OS or DSS were calculated as hazard ratios (HRs)
with 95% confidence intervals (CIs).
All tests were 2-tailed, and a P-value <0.05 was considered
statistically significant. Statistical analyses were performed




During the period from 2003 to 2009, a total of 381,644
cases of invasive mammary carcinoma were registered in
the SEER database; in comparison, only 142 cases of inva-
sive NEC were registered, which comprised <0.1% of total
invasive carcinomas of the breast, much less than the 2-5%
rate reported by the World Health Organization [13].
Using the rate session in the SEER *Stat software (version
7.1.0; Surveillance Research Program, NCI, Bethesda, MD),we calculated age-adjusted incidence rates for NEC of the
breast as 0.23 per 1 million-years in all populations
(95% CI: 0.18-0.29), 0.41 per 1 million-years in the female
population (95% CI: 0.31-0.53), and 0.01 per 1 million-years
in the male population (95% CI: 0.00-0.06).
Clinicopathologic characteristics
The clinicopathologic characteristics of the 142 NEC
patients were compared with those of IMC-NOS, and the
results are summarized in Table 1.
Age, sex, and ethnicity
The mean age at diagnosis of patients with NEC was
64 years (range 26–99 years; median 63 years). NEC
patients were significantly older (P = 0.029) than those
with IMC-NOS (range 10–114 years; mean 61 years;
median 61 years).
The distribution of ethnicity in cases of NEC of the
breast was similar to that in cases of IMC-NOS (Table 1).
There were proportionally more males with NEC than
with IMC-NOS (2.1% vs. 0.8%) but is not statistically
significant (P = 0.06) (Table 1).
Stage at diagnosis
Tumor size (T stage) At diagnosis, NEC tumors were
significantly larger than IMC-NOS tumors (P < 0.0001)
(Table 1). The mean NEC size was 32 mm, whereas the
mean IMC-NOS size was 23 mm.
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in the NEC group than in the IMC-NOS group had
positive regional lymph nodes at the time of diagnosis
(borderline significant, P = 0.05) (Table 1). Excluding cases
whose lymph node status was unknown, 43% of NEC cases
and 34% of IMC-NOS cases presented with lymph node
metastasis at the time of diagnosis.
TNM stage The NEC cases presented with a higher TNM
stage than the IMC-NOS cases (P < 0.0001) (Table 1).
There were more patients with stage II-IV disease in the
NEC group than in the IMC-NOS group. Whereas most
of the IMC-NOS group presented with stage I disease,
NEC patients most often presented with stage II disease,
indicating either large tumor size or regional lymph node
metastasis at the time of diagnosis.A Stage I and II (OS)
C Stage I and II (DSS)
P < 0.0001                                          
P < 0.0001                                          
Figure 1 Overall survival (OS) and disease-specific survival (DSS) com
mammary carcinoma, not otherwise specified (IMC) diagnosed betwe
in IMC-NOS in both early stage disease (A and C) and advanced stage diseTumor grade
The tumors of the NEC group were of significantly
higher histologic grade than those of the IMC-NOS group
(P < 0.0001) (Table 1). Most of NEC tumors were grade III,
whereas most of IMC-NOS tumors were grade II.
Receptor status
Most NECs of the breast were ER and PR positive. How-
ever, fewer NECs were ER and/or PR positive (67.9%) than
IMC-NOS (79.7%) (Table 1). HER2 status is not available
from the SEER database.
Survival
The median survival of patients with NEC was 26 months
(interquartile range [IQR], 12–48 months), which was
much shorter than that of patients with IMC-NOSB Stage III and IV (OS)
D Stage III and IV (DSS)
              P < 0.0001
              P < 0.0001
parisons between neuroendocrine carcinoma (NEC) and invasive
en 2003 and 2009. OS and DSS were significantly shorter in NEC than
ase (B and D).
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OS rates were also much lower in the NEC group than
in the IMC-NOS group (P < 0.0001) (Table 2). As ex-
pected, the more advanced the disease stage at the
time of presentation, the worse the clinical outcome.
Therefore, we stratified patients by stage, showing thatA Age B Tumor size
D Stage E Grade
P = 0.141 P = 0.001
G PR status H Surgery
P < 0.0001 P = 0.106
P = 0.018 P = 0.009
Figure 2 Factors affecting overall survival (OS) of mammary NEC. Age
(E), estrogen receptor (ER) and progesterone receptor (PR) status (F, G), surpatients with stage I, II or III disease in the NEC group
had lower OS rate than patients in the IMC-NOS group
with the same stage disease (Table 2). In addition, sur-
vival analyses showed worse OS and DSS in stage I-II
NEC than that in IMC, NOS patients with the same
stage (Figure 1A, 1C). Similar results were seen forC LN
F ER status
P = 0.125
   I Radiation
P = 0.008
P = 0.341
(A), tumor size (B), lymph node status (C), stage (D), histologic grade
gical resection (H) and radiation therapy (I) were analyzed.
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(Figure 1B, 1D).
Prognostic factors
Univariate analysis by the Kaplan-Meier method showed
that larger tumor size (>20 mm), higher tumor stage,Table 3 Univariate survival analysis (Kaplan-Meier) in selected
to characteristics
Characteristics 5-year DSS
n Survival rate (95% CI) HR (95% CI)
Sex
Male 2 Not reached
Female 133 66.2 (54.2-75.7) Not reached
Age (year)
≤60 55 67.9 (43.0-83.8)
>60 80 63.7 (49.2-75.1) 1.56 (0.74-3.32)
Race
White 114 68.9 (55.4-78.9)
Black 13 63.3 (28.6-84.6) 1.63 (0.56-4.70)
Other 8 Not reached 3.15 (1.08-9.19)
AJCC TNM stage
I 32 84.3 (43.2-96.6)
II 49 82.6 (64.4-92.0) 2.14 (0.44-10.4)
III 16 58.2 (21.0-82.8) 5.75 (1.05-31.5)
IV 32 20.7 (5.70-42.1) 18.0 (4.14-78.6)
LN
Negative 52 84.2 (58.1-94.7)
Positive 38 72.1 (48.8-86.1) 2.93(0.87-9.81)
Size (mm)
≤20 73 81.8 (65.1-90.9)
>20 48 53.4 (34.7-68.9) 4.82 (2.08-11.2)
Grade
I 15 77.8 (31.6-94.7)
II 29 74.2 (41.3-90.4) 1.12 (0.22-5.78)
III 58 68.0 (51.0-80.2) 2.09 (0.47-9.28)
ER status
Negative 36 Not reached
Positive 72 66.0 (49.7-78.1) 0.85 (0.58-1.26)
PR status
Negative 58 60.8 (40.3-76.2)
Positive 48 71.8 (53.3-84.0) 0.78 (0.52-1.15)
Radiation
No 85 69.5 (54.1-80.6)
Yes 50 62.0 (41.8-76.9) 1.10 (0.55-2.21)
Surgery
No 28 40.6 (17.6-62.6)
Yes 107 73.2 (59.7-82.8) 0.34 (0.16-0.69)
Data from the Surveillance, Epidemiology and End Results Program, 2003 to 2009. N
survival; n, number of cases; HR, hazard ratio; NS, not significant; CI, confidence inte
receptor; PR, progesterone receptor.negative ER/PR status, and lack of surgical treatment
were associated with shorter OS in the NEC cohort
(Figure 2, Table 3). Older age (>60 years), larger tumor
size (>20 mm), higher tumor stage, and lack of surgical
treatment were associated with shorter DSS in the NEC
cohort (Figure 3, Table 3). In multivariate analysis, onlysubgroups of patients with NEC of the breast according
5-year OS
P Survival rate (95% CI) HR (95% CI) P
NS NS
Not reached
54.1 (42.7-64.3) 0.39 (0.05-2.84)
NS NS
59.1 (37.6-75.4)
49.5 (35.8-61.8) 1.58 (0.85-2.91)
0.031 NS
55.4 (42.8-66.4)
58.0 (26.1-80.2) 1.27 (0.50-3.25)
Not reached 2.39 (0.94-6.11)
<0.0001 <0.0001
74.4 (43.4-90.0)
73.9 (56.3-85.3) 1.15 (0.42-3.14)
42.2 (14.3-68.2) 3.26 (1.09-9.75)
17.1 (4.72-35.9) 6.92 (2.78-17.2)
NS NS
72.8 (49.6-86.7)
62.7 (41.8-77.9) 1.96 (0.82-4.68)
<0.0001 0.002
67.9 (52.1-79.5)
44.4 (27.7-59.9) 2.70 (1.45-5.03)
NS NS
70.0 (29.9-90.0)
59.6 (31.6-79.3) 1.18 (0.31-4.46)
54.3 (38.9-67.3) 2.39 (0.72-7.98)
NS 0.01
Not reached
64.8 (48.7-77.0) 0.65 (0.47-0.90)
NS 0.022
45.6 (27.8-61.7)
71.8 (53.3-84.0) 0.66 (0.46-0.94)
NS NS
50.2 (35.4-63.2)
58.3 (39.0-73.4) 0.75 (0.42-1.36)
0.003 0.012
34.6 (14.9-55.3)
58.9 (45.9-69.9) 0.45 (0.25-0.84)
EC, neuroendocrine carcinoma; DSS, disease-specific survival; OS, overall
rval; TNM, tumor-lymph nodes-metastasis; LN, lymph node; ER, estrogen
LN
ER status            
A Age B Tumor size C
D Stage E Grade F
G PR status H Surgery    I Radiation                                  
P = 0.241                                                     P = 0.0001                                                   P = 0.068
P = 0.203                                                    P = 0.002                                                    P = 0.791
P < 0.0001                                                   P = 0.355                                                    P = 0.427
Figure 3 Factors affecting disease-specific survival (DSS) of mammary NEC. Age (A), tumor size (B), lymph node status (C), stage (D), histologic
grade (E), estrogen receptor (ER) and progesterone receptor (PR) status (F, G), surgical resection (H) and radiation therapy (I) were analyzed.
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ently prognostic for poor OS (P = 0.012 and P < 0.0001,
respectively). Negative PR status, positive lymph node status
and lack of surgery treatment were the only independ-
ent prognostic factor for DSS (P = 0.006, P < 0.0001 and
P = 0.041) (Table 4).To determine whether neuroendocrine differentiation
itself has prognostic significance, we pooled the NEC
and IMC-NOS cases together and performed multivari-
ate analyses based on all the known prognostic factors
in addition to neuroendocrine differentiation. As shown in
Table 5, neuroendocrine differentiation was an independent
Table 4 Multivariate analysis of independent prognostic factors for DSS and OS in patients with NEC of the breast
Group DSS OS
HR (95% CI) P HR (95% CI) P
Age (>60 years vs ≤60 years) 1.82 (0.86-3.85) NS 2.02 (1.17-3.52) 0.012
Size (>20 mm vs ≤20 mm) 1.82 (0.91-3.64) NS 1.44 (0.89-2.32) NS
LN (positive vs negative) 2.54 (1.59-4.06) <0.0001 2.05 (1.51-2.80) <0.0001
Grade (III vs I, II) 1.18 (0.80-1.74) NS 1.24 (0.95-1.62) NS
ER status (positive vs negative) 1.23 (0.82-1.84) NS 0.95 (0.69-1.32) NS
PR status (positive vs negative) 0.59(0.41-0.86) 0.006 0.82 (0.60-1.10) NS
Radiation (yes vs no) 0.79 (0.41-1.55) NS 0.76 (0.47-1.22) NS
Surgery (yes vs no) 0.39 (0.16-0.96) 0.041 0.57 (0.27-1.20) NS
DSS, disease-specific survival; OS, overall survival; NEC; neuroendocrine carcinoma; HR, hazard ratio; CI, confidence interval; NS, not significant; LN, lymph node; ER,
estrogen receptor; PR, progesterone receptor.
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P < 0.0001).
Clinical Significance of 2003 WHO Diagnostic Criteria for
Mammary NEC
Mammary NEC has been a controversial entity. Variable
clinical outcomes have been reported by different studies,
partially due to inconsistent diagnostic criteria. In 2003,
WHO implemented diagnostic criteria for this entity,
requiring that >50% of the tumor cells express neuro-
endocrine markers.
We identified 72 additional mammary NEC based on the
same ICD codes in the SEER database between 1998–2002,
when the diagnostic criteria for mammary NEC were not
uniformly applied. We performed survival analyses on those
72 cases, and showed no statistically significant difference
in DSS for early stage (stage I-II) patients, and no difference
in either OS or DSS in advanced stage (stage II-IV) patients
(Figure 4). These results suggest that before 2003, some of
the mammary NEC included in the SEER database may beTable 5 Multivariate analysis of independent prognostic facto
the breast (pooled NEC and IMC-NOS)
Group DSS
HR (95% CI)
Age, years (>60 vs ≤60) 1.14 (1.13-1.16)
Tumor size, mm (>20 vs ≤20) 1.65 (1.64-1.66)
LN (positive vs negative) 1.98 (1.97-2.00)
Grade (III vs I, II) 1.26 (1.25-1.27)
ER status (positive vs negative) 0.82 (0.81-0.83)
PR status (positive vs negative) 0.88 (0.87-0.89)
Neuroendocrine (positive vs negative) 1.80 (1.36-2.37)
Radiation (yes vs no) 0.90 (0.89-0.91)
Surgery (yes vs no) 0.44 (0.43-0.45)
DSS, disease-specific survival; OS, overall survival; NEC; neuroendocrine carcinoma; I
ratio; CI, confidence interval; LN, lymph node; ER, estrogen receptor; PR, progesterothose cases with focal NE differentiation (i.e., <50% of the
tumor cells expressing neuroendocrine markers). As studies
have shown that focal NE differentiation has no prognos-
tic significance as compared with mammary carcinoma,
NOS [5,14], our results from the SEER database between
1998–2002 further confirm the importance of applying
2003 diagnostic criteria for mammary NEC.
Discussion
NEC of the breast is a rare disease. Only 6 case series
have been reported in the literature, the largest comprising
74 cases [6-11]. With the 142 SEER cases reported here,
this is the largest series reported to date and the first
population study of mammary NEC.
The incidence of NEC of the breast has not been re-
ported. Although NEC was estimated in 2003 to represent
2-5% of breast carcinomas [13], we found from our analysis
of SEER data released in April 2012 that the incidence of
mammary NEC is much lower. The age-adjusted incidence
is 0.41 per 1 million-years in the female population of thers for DSS and OS in patients with invasive carcinoma of
OS
P HR (95% CI) P
<0.0001 2.62 (2.60-2.65) <0.0001
<0.0001 1.34 (1.33-1.35) <0.0001
<0.0001 1.64 (1.63-1.65) <0.0001
<0.0001 1.12 (1.11-1.13) <0.0001
<0.0001 0.90 (0.89-0.91) <0.0001
<0.0001 0.93 (0.92-0.94) <0.0001
<0.0001 1.84 (1.50-2.26) <0.0001
<0.0001 0.75 (0.74-0.76) <0.0001
<0.0001 0.45 (0.46-0.47) <0.0001
MC-NOS, invasive mammary carcinoma, not otherwise specified; HR, hazard
ne receptor.
A Stage I and II (OS) B Stage III and IV (OS)
C Stage I and II (DSS) D Stage  III and IV (DSS)
P = 0.097                                                                              P = 0.797
P < 0.0001                                                                             P = 0.8966
Figure 4 Overall survival (OS) and disease-specific survival (DSS) comparisons between neuroendocrine carcinoma (NEC) and invasive
mammary carcinoma, not otherwise specified (IMC) diagnosed between 1998 and 2002. Although OS was significantly shorter in NEC than
in IMC-NOS in early stage disease (A), there was no difference in DSS between NEC and IMC-NOS (C). There was no difference in both OS and
DSS between NEC and IMC-NOS in advanced stage disease (B and D).
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omas. Despite the low incidence of male breast carcinomas
overall, the SEER data showed that NEC was proportionally
more common in men than IMC-NOS (2.1% of all NEC;
0.8% of all IMC-NOS).
Because mammary NEC has not been well studied,
its clinicopathologic features and outcome are poorly
characterized. Among the 6 reported series studies, 2
studies with 35 and 10 patients showed no difference
in outcome from IMC-NOS [6,9], and 3 studies with
13, 12, and 7 patients showed better prognosis in NEC
[7-10]. The present study, representing a substantially
larger cohort, showed a much poorer clinical outcome
for mammary NEC than for IMC-NOS. This result was
consistent with our previous report of 74 NEC cases from
a single institution [11]. In the present study, median
survival duration of NEC cases was much shorter thanthat of IMC-NOS cases (26 months in NEC; 34 months
in IMC-NOS).
Like our previous study, this population-based study
showed that a majority of the NECs were ER and/or PR
positive (68%), though the proportion of ER- and PR-
positive cases was slightly lower than that previously
reported. The present study also showed that NEC
tended to occur in older patients (mean age 64 years)
than IMC-NOS (mean 61 years-old) and to present at
higher clinical stages with larger tumors (mean 32 mm
compared to 23 mm in IMC-NOS) and more frequent
regional lymph node metastasis. Although NEC was
often associated with less favorable clinicopathologic
features, multivariate analyses showed that only older age
(>60 years) and positive lymph node status were independ-
ent prognostic factors for OS, and only positive lymph node
status, negative PR status and lack of surgical treatment
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compared NEC with IMC-NOS at the same clinical stage,
both OS and DSS were statistically shorter in NEC than in
IMC-NOS. Interestingly, when we pooled all the mam-
mary carcinoma together, including NEC, and analyzed
independent prognostic factors using multivariate ana-
lysis, neuroendocrine differentiation was revealed as an
adverse prognostic factor independent of other prog-
nostic factors, including greater age, larger tumor size,
and higher histologic grade.
Conclusions
In summary, this population-based study showed that
NEC is an aggressive mammary carcinoma subtype with
significantly shorter OS and DSS than IMC-NOS. It tends
to present at greater age, with larger tumor size, higher
histologic grade, and higher clinical stage. NEC also tends
to be ER/PR positive, but positive ER status does not appear
to confer a prognostic benefit as it does in other invasive
mammary carcinomas. As information regarding systemic
treatment, including hormonal therapy and chemotherapy,
was not available in the SEER database, we could not
analyze whether such therapies would make a difference in
outcome in this disease. Our multivariate analyses showed,
however, that radiation therapy did not prolong survival of
patients with mammary NEC.
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